CIPROXIN 500

Riik: Indoneesia

keel: indoneesia

Allikas: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Toimeaine:

CIPROFLOXACIN HYDROCHLORIDE

Saadav alates:

BAYER INDONESIA - Indonesia

INN (Rahvusvaheline Nimetus):

CIPROFLOXACIN HYDROCHLORIDE

Annus:

500 MG

Ravimvorm:

TABLET SALUT SELAPUT

Ühikuid pakis:

DRUM, FOILBAG @ 25-75 KG

Valmistatud:

BAYER AG - GERMANY

Loa andmise kuupäev:

2019-04-12

Toote omadused

CIPROXIN
®
FILM-COATED TABLET
Important information, please read carefully! COMPOSITION
Ciproxin
®
500:
1
film-coated
tablet
contains
582 mg
ciprofloxacin
hydrochloride
monohydrate,
correspond
to
500 mg
ciprofloxacin. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Fluoroquinolones
ATC Code: J01MA02
Ciprofloxacin is a new substance developed by Bayer AG belonging to
the quinolone carboxylic acid group. The substance
has a good bactericidal effect against a broad spectrum of bacteria.
PHARMACODINAMIC PROPERTIES
MECHANISM OF ACTION
The bactericidal action of ciprofloxacin results from inhibition of
bacterial type II topoisomerases (DNA gyrase and
topoisomerase IV), which are required for bacterial DNA replication,
transcription, repair, and recombination.
MECHANISM OF RESISTANCE
_In-vitro _resistance to ciprofloxacin can be acquired through a
stepwise process by target site mutations in both DNA gyrase
and topoisomerase IV. The degree of cross-resistance between
ciprofloxacin and other fluoroquinolones that results is
variable. Single mutations may not result in clinical resistance, but
multiple mutations generally result in clinical resistance to
many or all active substances within the class.
Impermeability and/or active substance efflux pump mechanisms of
resistance may have a variable effect on susceptibility
to fluoroquinolones, which depends on the physiochemical properties of
the various active substances within the class and
the affinity of transport systems for each active substance. All
_in-vitro _mechanisms of resistance are commonly observed in
clinical
isolates.
Resistance
mechanisms
that
inactivate
other
antibiotics
such
as
permeation
barriers
(common
in
_Pseudomonas aeruginosa_) and efflux mechanisms may affect
susceptibility to ciprofloxacin.
Plasmid-mediated resistance encoded by qnr-genes has been reported.
The bacterial genus and species listed below have been shown to
commonly be susceptible to ciprofloxacin in vitro:
AEROBIC GRAM-POSITIVE MICROORGANISMS
_Bacillus anthracis _
_Streptococ